These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24430033)

  • 1. [The results of the Russian multicenter open observational non-comparative study on the efficacy and safety of valdoxan (agomelatin) in the treatment of patients with major depressive disorder and insomnia (the VIVALDI study)].
    Poluéktov MG; Levin YI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):39-44. PubMed ID: 24430033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical experience of the use of agomelatine in the treatment of patients with depression and chronic brain ischemia].
    Antonen EG; Nikitina MV; Kruchek MM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(12):79-85. PubMed ID: 26978498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major depressive disorder, sleep EEG and agomelatine: an open-label study.
    Quera Salva MA; Vanier B; Laredo J; Hartley S; Chapotot F; Moulin C; Lofaso F; Guilleminault C
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):691-6. PubMed ID: 17477886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
    Brooks S; Jacobs GE; de Boer P; Kent JM; Van Nueten L; van Amerongen G; Zuiker R; Kezic I; Luthringer R; van der Ark P; van Gerven JM; Drevets W
    J Psychopharmacol; 2019 Feb; 33(2):202-209. PubMed ID: 30644312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
    Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
    J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.
    Quera-Salva MA; Lemoine P; Guilleminault C
    Hum Psychopharmacol; 2010 Apr; 25(3):222-9. PubMed ID: 20373473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine.
    Shen J; Chung SA; Kayumov L; Moller H; Hossain N; Wang X; Deb P; Sun F; Huang X; Novak M; Appleton D; Shapiro CM
    Can J Psychiatry; 2006 Jan; 51(1):27-34. PubMed ID: 16491981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The results of Russian multicenter open-label observational study of the efficacy and safety of мelaxen (melatonin) for the treatment of disordered sleep in patients with chronic cerebral ischemia].
    Poluéktov MG; Levin IaI; Boĭko AN; Skoromets AA; Bel'skaia GN; Gustov AV; Doronin BM; Poverennova IE; Spirin NN; Iakupov EZ
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9):26-31. PubMed ID: 23235408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of agomelatine and mirtazapine on sleep disturbances in major depressive disorder: evidence from polysomnographic and resting-state functional connectivity analyses.
    Mi WF; Tabarak S; Wang L; Zhang SZ; Lin X; Du LT; Liu Z; Bao YP; Gao XJ; Zhang WH; Wang XQ; Fan TT; Li LZ; Hao XN; Fu Y; Shi Y; Guo LH; Sun HQ; Liu L; Si TM; Zhang HY; Lu L; Li SX
    Sleep; 2020 Nov; 43(11):. PubMed ID: 32406918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis.
    Liguori C; Ferini-Strambi L; Izzi F; Mari L; Manfredi N; D'Elia A; Mercuri NB; Placidi F
    Br J Clin Pharmacol; 2019 Jan; 85(1):240-244. PubMed ID: 30328132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
    Zajecka J; Schatzberg A; Stahl S; Shah A; Caputo A; Post A
    J Clin Psychopharmacol; 2010 Apr; 30(2):135-44. PubMed ID: 20520286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sertraline on breathing in depressed patients without moderate-to-severe sleep-related breathing disorders.
    Zhang B; Hao Y; Jia F; Li X; Tang Y; Zheng H; Liu W
    Sleep Breath; 2015 Dec; 19(4):1377-86. PubMed ID: 25758299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Problems of depressive insomnia].
    Tarakanova EA; Ivanchuk ÉG; Rostovshchikov VV
    Vestn Ross Akad Med Nauk; 2014; (7-8):153-7. PubMed ID: 25563018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
    Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
    Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep characteristics of menopausal insomnia: a polysomnographic study.
    Terashima K; Mikami A; Tachibana N; Kumano-Go T; Teshima Y; Sugita Y; Takeda M
    Psychiatry Clin Neurosci; 2004 Apr; 58(2):179-85. PubMed ID: 15009824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleep ultradian cycling: Statistical distribution and links with other sleep variables, depression, insomnia and sleepiness-A retrospective study on 2,312 polysomnograms.
    Le Bon O; Lanquart JP; Hein M; Loas G
    Psychiatry Res; 2019 Sep; 279():140-147. PubMed ID: 30819535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical-psychopathological aspects of therapeutic effects of agomelatine (valdoxan) and its place in perfection of methods of therapy of postschizophrenic depressive disorders].
    Panteleyeva GP; Abramova LI; Novozhenova TE; Subbotskaya NV; Tikhonov DV; Yumatova PE; Nikiforova IY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(3):59-69. PubMed ID: 29652308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.